News | January 16, 2015

Study Validates Non-Contrast Enhanced MRA for Detecting Renal Artery

Outcomes of international multi-center trial sponsored by Toshiba published in American Journal of Roentgenology

Clinical trial, MRI system, Peripheral Artery Disease, Renal Artery Stenosis

Image courtesy of Toshiba


January 16, 2015 — Non-contrast enhanced MR angiography (MRA) techniques have attracted interest in the medical community for diagnosing renal artery stenosis, as it eliminates the need for contrast agents used with computed tomography angiography (CTA). In an international multi-center trial REACT (REnal Artery Contrast-free Trial), Toshiba’s Time-Spatial Labeling Inversion Pulse (Time-SLIP) is validated as a technique for non-contrast vascular imaging while providing an accurate and non-invasive method for diagnosing patients.

The results from the multi-center trial showed no statistical differences between non-contrast MRA and CTA in terms of their ability to visualize renal artery stenosis. The results from the trial were published in the January 2015 issue of American Journal of Roentgenology.

Toshio Takiguchi, president, Toshiba Medical Systems Corporation (TMSC) comments: “The REACT study has proved that it is now possible to detect renal artery stenosis without using contrast agents. Time-SLIP eliminates the need for gadolinium-based contrast agents, which results in safer and more comfortable examinations. Not only do these non-invasive and painless techniques eliminate the risks associated with gadolinium-based contrast agents, but they also require less setup time for clinicians, resulting in MR exams that are more comfortable for the patient and can be completed more quickly without compromising image quality.”

The trial consisted of 75 patients in collaboration with seven medical centers in five countries: the United States, Spain, China, France and Japan. All subjects underwent medically required non-contrast renal MRA exams, using the 1.5T Vantage Atlas and Vantage Titan MR systems, as well as CT angiography for the evaluation of renal artery stenosis.

For more information: www.medical.toshiba.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now